Ditte Marie Lindhardt Saunte

Prof. Ditte Marie Lindhardt Saunte

Region Zealand, Roskilde, Sjælland, Denmark
+1
orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 November 2017 in JAMA
Verified
Journal Article
Closed access
PDF file
DSDitte Marie Lindhardt Saunte
Ditte Marie Lindhardt Saunte
GJGregor Borut Ernst Jemec
Gregor Borut Ernst Jemec
Importance Hidradenitis suppurativa (HS) is relatively common, with the prevalence of 0.05% to 4.10%, yet many patients receive inadequate treatment. Objective To review the diagnosis, epidemiology, and treatment of HS with an emphasis on advances in the last 5 years. Evidence Review A literature search was conducted using PubMed, MEDLINE (Medical Subject Headings [MeSH]), and EMBASE to include recently published treatment studies (searched from September 1, 2011, to May 1, 2017). Reviews, guidelines, conference abstracts, and studies with less than 10 patients were excluded. Furthermore, internet searches for guidelines on hidradenitis suppurativa using Baidu, Bing, Google, and Qwant browsers were performed. Findings The diagnosis of HS is made by lesion morphology (nodules, abscesses, tunnels, and scars), location (axillae, inframammary folds, groin, perigenital, or perineal), and lesion progression (2 recurrences within 6 months or chronic or persistent lesions for ≥3 months). HS is more common than was previously thought based on epidemiological analysis (0.05%-4.10%). Disability from HS can be significant. Patients with HS may have significant comorbidities (eg, obesity, metabolic syndrome, diabetes, and arthritis) and increased all-cause mortality (incidence rate ratio, 1.35 [95% CI, 1.15-1.59]). Antibiotic treatment with combinations of clindamycin and rifampicin, or ertapenem followed by combination rifampicin, moxifloxacin, and metronidazole for 6 months is effective. Adalimumab is effective in a significant proportion of patients and treatment with IL-1 and IL-12 receptor subunit beta 1 (Rb1) antibodies may also be useful. Tissue-sparing surgical techniques and carbon dioxide laser treatments also are available, but the evidence on clinical outcomes with these approaches is limited. Conclusions and Relevance Hidradenitis suppurativa is more common than previously thought and may be treated by an array of pharmacological and surgical techniques. Hidradenitis suppurativa should be considered in the differential diagnosis of nodular lesions or sinus tracts present in the axillae, groin, perineal, and mammillary fold regions.

21 July 2015 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
DSDitte Marie Lindhardt Saunte
Ditte Marie Lindhardt Saunte
JBJ. Boer
J. Boer
ASA. Stratigos
A. Stratigos
Jacek C. SzepietowskiJacek C. Szepietowski
Jacek C. Szepietowski
IHI. Hamzavi
I. Hamzavi
GJG.B.E. Jemec
G.B.E. Jemec

1 September 2017 in JAMA Dermatology
Verified
Journal Article
Open access
PDF file
HRHans Christian Ring
Hans Christian Ring
JTJonathan Thorsen
Jonathan Thorsen
DSDitte Marie Lindhardt Saunte
Ditte Marie Lindhardt Saunte
BLBerit Lilje
Berit Lilje
LBLene Bay
Lene Bay
GJGregor Borut Jemec
Gregor Borut Jemec
Hidradenitis suppurativa (HS) is a chronic, inflammatory skin disease of the hair follicle defined by recurrent nodules, tunnels (sinus tracts), and scarring involving the intertriginous regions.1 The nodules may progressively expand to abscesses and subsequently rupture, causing suppuration and malodorous discharge.2 The prevalence of HS has been estimated to be among 1% to 4% of the European populations.3-5

31 August 2016 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
DSDitte Marie Lindhardt Saunte
Ditte Marie Lindhardt Saunte
UMU. Mrowietz
U. Mrowietz
LPL. Puig
L. Puig
CZC. Zachariae
C. Zachariae

20 March 2020 in Frontiers in Cellular and Infection Microbiology
Verified
Journal Article
Open access
PDF file
DSDitte Marie Lindhardt Saunte
Ditte Marie Lindhardt Saunte
GGGeorge Gaitanis
George Gaitanis
RHRoderick James Hay
Roderick James Hay
Yeasts of the genus, Malassezia, formerly known as Pityrosporum, are lipophilic yeasts, which are a part of the normal skin flora (microbiome). Malassezia colonize the human skin after birth and must therefore, as commensals, be normally tolerated by the human immune system. The Malassezia yeasts also have a pathogenic potential where they can, under appropriate conditions, invade the stratum corneum and interact with the host immune system, both directly but also through chemical mediators. The species distribution on the skin and the pathogenetic potential of the yeast varies between different Malassezia related diseases such as head and neck dermatitis, seborrheic dermatitis, pityriasis versicolor, and Malassezia folliculitis. The diagnostic methods used to confirm the presence of Malassezia yeasts include direct microcopy, culture based methods (often a combination of morphological features of the isolate combined with biochemical test), molecular based methods such as Polymerase Chain Reaction techniques, and Matrix Assisted Laser Desorption/Ionization—Time Of Flight mass spectrometry and the chemical imprint method Raman spectroscopy. Skin diseases caused by Malassezia are usually treated with antifungal therapy and if there are associated inflammatory skin mechanisms this is often supplemented by anti-inflammatory therapy. The aim of this paper is to provide an overview of Malassezia related skin disease, diagnostic methods and treatment options.

19 December 2024 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Open access
Christos C. ZouboulisChristos C. Zouboulis
Christos C. Zouboulis
FBFalk G. Bechara
Falk G. Bechara
FBF. Benhadou
F. Benhadou
VBVincenzo Bettoli
Vincenzo Bettoli
ZMZ. Bukvić Mokos
Z. Bukvić Mokos
GJG. B. E. Jemec
G. B. E. Jemec
Introduction: This second part of the S2k guidelines is an update of the 2015 S1 European guidelines.Objective: These guidelines aim to provide an accepted decision aid for the selection, implementation and assessment of appropriate and sufficient therapy for patients with hidradenitis suppurativa/acne inversa (HS).Methods: The chapters have been selected after a Delphi procedure among the experts/authors. Certain passages have been adopted without changes from the previous version. Potential treatment complications are not included, being beyond the scope of these guidelines.Results: Since the S1 guidelines publication, validation of new therapeutic approaches has almost completely overhauled the knowledge in the field of HS treatment. Inflammatory nodules/abscesses/draining tunnels are the primary lesions, which enable the classification of the disease severity by new validated tools. In relation to the degree of detectable inflammation, HS is classified into the inflammatory and the predominantly non‐inflammatory forms. While the intensity of the inflammatory form can be subdivided by the IHS4 classification in mild, moderate and severe HS and is treated by medication accordingly, the decision on surgical treatment of the predominantly non‐inflammatory form is based on the Hurley stage of the affected localization. The effectiveness of oral tetracyclines as an alternative to the oral combination of clindamycin/rifampicin should be noted. The duration of systemic antibiotic therapy can be shortened by a 5‐day intravenous clindamycin treatment. Adalimumab, secukinumab and bimekizumab subcutaneous administration has been approved by the EMA for the treatment of moderate‐to‐severe HS. Various surgical procedures are available for the predominantly non‐inflammatory form of the disease. The combination of a medical therapy to reduce inflammation with a surgical procedure to remove irreversible tissue damage is currently considered a holistic therapeutic approach.Conclusions: Suitable therapeutic options while considering HS severity in the therapeutic algorithm according to standardized criteria are aimed at ensuring a proper therapy.